Vortioxetine hydrobromide troban BML275 dihydrochloride

BML275 dihydrochloride

so the drug does not have such catastrophic effects on animals or plants

and potential for combination in preclinical models

route of elimination and binding site on their target pancreatic β cell receptor

Vortioxetine hydrobromide troban BML275 dihydrochlorideVortioxetine, also known as Lu AA21004, is an atypical antidepressant, and was approved in 2013 by the U. S. FDA for the treatment of major depressive disorder (MDD) in adults. Vortioxetine is a so called "serotonin modulator and stimulator." It has been shown to possess the following pharmacological actions: Serotonin transporter (SERT) blocker (i. e. serotonin reuptake inhibitor (SRI)) Ki (binding affinity) = 1. 6 nM, IC50 = 5. 4 nM; Norepinephrine